Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine Pegfilgrastim is a long-acting version of the oncology supportive care medicine…
Sandoz Scientific Standalone Event “Combat Infections to Save Lives” aims at increasing access to information in the field of antibiotic therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA) First event in the field of anti-in…
Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximabEfficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match refer…
Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and qualityPegfilgrastim is a long-acting version of oncology medicine filgrastim — Sandoz is the European market …
Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indicationsEntresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansionExcluding G…
Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indicationsEntresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansionExcluding G…
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile1Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatme…
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis1Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine i…
Expected investment will amount to approximately USD 50mDecision to expand underlines confidence in growth potential of businessModern campus facility will promote more collaborative ways of working Holzkirchen, August 29, 2017 — Sandoz, the generic ph…
Lancet Haematology publishes data from ASSIST-FL study of Sandoz Rixathon®, in patients with previously untreated advanced follicular lymphomaASSIST-FL, results of which were first announced in December 2017, achieved its primary endpoint1Rixathon® rec…